EZH2 and cancer: Furthermore, MeDIP sequencing of 51 tumor and 53 benign prostate samples has revealed there are more than 147,000 cancer-associated epigenetic alterations, there are significant global methylation pattern differences associated with TMPRSS2-ERG rearrangement status, and hypermethylation of miR-26a can be involved in ERG rearrangement-independent EZH2 activation (86).